Eisai is coming to believe that there's no place like home. The Japanese drugmaker says it's planning to pull back in the U.S. and refocus on East Asia, and not just because markets such as...
Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
Eli Lilly ($LLY) CEO John Lechleiter (photo) says price squeezes in Europe and Japan will be key challenges to his company's sales in 2012, one week after the company predicted a bigger-than-expected
The "do not disturb" signs may be out for pharma reps at more U.S. medical practices these days. But according to a new study by Cegedim Strategic Data, sales reps are almost as popular with doctors
India's Lupin has made a second foray into Japan, striking a deal to buy the Tokyo-based injectables maker I'Rom Pharmaceutical. The buyout follows Lupin's acquisition of Kyowa Pharmaceuticals, which
Israel's Given Imaging ($GIVN) has begun the pivotal PillCam COLON 2 study to support its planned regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency. The study will evaluate
Looking for a local beachhead in Japan? Private equity firm Tokio Marine Capital is looking to sell the drugmaker Showa Yakuhin Kako in a deal that could bring in as much as $905 million, sources
As Japanese drugmakers look outside their home market for acquisitions and growth, Big Pharma is moving in. With sales growth slowing to a crawl in the U.S. and Europe, global drugmakers have...
Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek